Geneius Biotechnology
Natick, US · Founded 2015 · Delaware corporation
Geneius develops and commercializes autologous adoptive T-cell therapies designed to treat cancer by targeting the mutations driving a patient's disease. The company aims to deliver its immunotherapy through community oncologists at a lower cost than CAR-T, in the oncology/immunotherapy space.
Founders & leadership
Geneius Biotechnology was founded in 2015 by Alfred Slanetz.
AS
Alfred SlanetzFounder
Board
RM
Ryan M. LaneBoard director
Reported raises · per SEC filings
Form D private placements$8.3M disclosed across 4 rounds · 2015–2017
▶$550KraisedSep 2018 · 7 investors · BiotechnologyRule 506(b)
▶$550KraisedSep 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alfred E. SlanetzExecutive Officer, Director
- Steven KloeblenDirector
- Offering amount
- $5M
- Amount sold
- $550K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.4MraisedJan 2016 · 20 investors · BiotechnologyRule 506(b)
▶$2.4MraisedJan 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alfred SlanetzExecutive Officer, Director
- Ryan LaneDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Sales commissions
- $70K
- Placement agents
- Roth Capital Partners
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.1MraisedJun 2015 · 45 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJun 2015 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan LaneDirector
- Alfred SlanetzExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- Sales commissions
- $45K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.3MraisedMar 2015 · 34 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2015 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan M. LaneDirector
- Alfred SlanetzExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.3M
- Sales commissions
- $210K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAgenus8 shared keywordsAgenus develops immunotherapies for cancer treatment, building a portfolio of antibody therapeutics, adoptive cell therapies, and adjuvant and vaccine platforms that work across the cancer immunity cycle. Its lead approach combines Botensilimab and Balstilimab to activate the immune system against cancer, with the aim of reducing reliance on chemotherapy, radiation, and surgery.
Amicus Therapeutics7 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Geneius Biotechnology for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Geneius Biotechnology do?
- Geneius develops and commercializes autologous adoptive T-cell therapies designed to treat cancer by targeting the mutations driving a patient's disease. The company aims to deliver its immunotherapy through community oncologists at a lower cost than CAR-T, in the oncology/immunotherapy space.
- Who founded Geneius Biotechnology?
- Geneius Biotechnology was founded by Alfred Slanetz in 2015.
- How much funding has Geneius Biotechnology raised?
- Geneius Biotechnology has disclosed $8.3M raised across 4 rounds.
- Where is Geneius Biotechnology headquartered?
- Geneius Biotechnology is headquartered in Natick, US.